In October 2013 Ancora Pharmaceuticals, Inc. was acquired by pharmaceutical manufacturer CordenPharma. Ancora had been focused on a proprietary carbohydrate synthesis technology platform developing immune system modulation therapeutics using this platform. The firm's products include vaccines against bacterial, parasitic, and viral infectious diseases, as well as therapeutics to treat cardiovascular and metabolic diseases. CordenPharma planned to pair Ancora's expertise in carbohydrate synthesis with its own expertise in process development, scale-up and GMP manufacturing capabilities to become the leading global supplier of synthetic carbohydrates for all applications, including: Glycoconjugate vaccine antigens, Immunomodulatory therapeutics, Tissue targeting / drug delivery motifs, Nutraceuticals, Analytical reagents and standards, Diagnostic reagents, and Defined content for glycomics research.
